LRRK2 and supranuclear palsy, progressive, 1: These effects may relate to cell-type specific expression patterns, or heterogeneity in pathology and disease states and understanding the underlying mechanisms will be fundamental in understanding disease mechanisms in PSP itself and validating LRRK2 as a therapeutic target.